Abstract: A sulfamato hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a process for preparing the same, intermediate compounds useful in those syntheses, and a treatment process that comprises administering a contemplated sulfamato hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
Type:
Grant
Filed:
September 30, 2002
Date of Patent:
October 5, 2004
Assignee:
Pharmacia Corporation
Inventors:
Gary A. DeCrescenzo, Joseph G. Rico, Terri L. Boehm, Jeffery N. Carroll, Darren J. Kassab, Deborah A. Mischke, Shashidhar Rao
Abstract: This invention relates to N-aroyl cyclic amine derivatives of formula (I): wherein: Y represents a bond, oxygen, or a group (CH2)n, wherein n represents 1, 2 or 3 m represents 1, 2 or 3; p represents 0 or 1; X is O,SC═O, SO2, or —CH═CH; Ar1 is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; any of which may be optionally substituted; Ar2 represents phenyl or a 5- or 5-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heterocyclyl group is substituted by R1 and further optional substituents; or Ar2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, O and S; R1 represents hydrogen, optionally substituted (C1-4)alkoxy, halo, cyano, optionally substituted (C1-16)alkyl, optionally substituted 5- or 6-membered heterocyclic ring containing up to 4 heteroatoms selected from N, O and S; or a pharmaceutical acc
Type:
Application
Filed:
April 15, 2004
Publication date:
September 30, 2004
Inventors:
Pascale Gaillard, Christopher Norbert Johnson, Riccardo Novelli, Roderick Alan Porter, Geoffrey Stemp, Kevin Michael Thewlis
Abstract: A compound of formula (I) wherein: R1 and R2, which may be the same or different, is each a hydrogen atom or a CF3, CF2H or CFH2 group, provided that when one of R?1 or R2 is a hydrogen atom the other is a CF3, CF2H or CFH2 group; and the salts, solvates or hydrates thereof. The compounds are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. The compounds may be expected to be of use in medicine, especially where the avoidance of side effects such as joint pain is desired.
Abstract: Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.
Type:
Application
Filed:
January 16, 2004
Publication date:
September 23, 2004
Inventors:
Robert Jiang, Tim Marquart, Jeff Zablocki, Elfatih Elzein, Venkata Palle, Prabha Ibrahim
Abstract: A sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
Type:
Grant
Filed:
December 1, 2000
Date of Patent:
September 21, 2004
Assignee:
G. D. Searle
Inventors:
Louis J. Bedell, Joseph J. McDonald, Thomas E. Barta, Daniel P. Becker, Shashidhar N. Rao, John N. Freskos, Brent V. Mischke, Daniel P. Getman, Gary A. DeCrescenzo, Clara I. Villamil
Abstract: A novel process is provided for the preparation of 4-aryl piperidines, and the useful intermediates obtained therein. These compounds are intermediates for the synthesis of melanocortin-4 receptor (MC-4R), which are useful for the treatment of disorders such as obesity, diabetes, male sexual dysfunction, and female sexual dysfunction.
Type:
Application
Filed:
March 8, 2004
Publication date:
September 16, 2004
Inventors:
Genevieve N. Boice, Karen M. Conrad, Edward G. Corley, Louis Matty, Jerry A. Murry, Cecile G. Savarin
Abstract: This invention relates to N-aroyl cyclic amine derivatives of formula (1), wherein X represents a bond, oxygen, NR3 or a group (CH2), wherein n represents 1, 2 or 3; Y represents CH2, CO, CH(OH), or CH2CH(OH); Het is an optionally substituted bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; Ar2 represents an optionally substituted phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S and their use as pharmaceuticals, specifically as orexin receptor antagonists.
Type:
Application
Filed:
April 26, 2004
Publication date:
September 16, 2004
Inventors:
Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
Abstract: The present invention relates to piperazine and piperidine derivatives, which are especially useful for treating or preventing neuronal damage, particularly damage associated with neurological diseases. These compounds are also useful for stimulating nerve growth. The invention also provides compositions comprising the compounds of the present invention and methods of utilizing those compositions for treating or preventing neuronal damage or for stimulating nerve growth.
Type:
Application
Filed:
October 2, 2003
Publication date:
September 16, 2004
Inventors:
David J. Lauffer, Martyn C. Botfield, Eckard Ottow
Abstract: Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.
Type:
Application
Filed:
January 16, 2004
Publication date:
September 9, 2004
Inventors:
Prabha Ibrahim, Kevin Shenk, Elfatih Elzein, Venkata Palle, Jeff Zablocki, Kenneth S. Rehder
Abstract: The invention provides compounds of formula (I):[Chemical formula should be inserted here. Please see paper copy] wherein: T is C(O) or S(O)2; W is C(O) or S(O)2; X is CH2, O or NH; Y is CR11 or N; n is 0, 1 or 2; m is 1 or, when Y is CR11 m is 0; R1 is optionally substituted aryl or optionally substituted heterocyclyl; R2, R3, R,4, R5, R6, R7 and R8 are, independently, hydrogen or C?1-6#191 alkyl; R9 is hydrogen or C1-C6 alkyl; R10 is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; and R11 is hydrogen or C1-C6 allkyl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis.
Type:
Application
Filed:
January 8, 2004
Publication date:
September 9, 2004
Inventors:
Richard Evans, Matthew Perry, Brian Springthorpe
Abstract: A compound of the formula:
[wherein R1 is a hydrocarbon group which may be substituted;
R2 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted;
R3 is halogen atoms, a carbamoyl group which may be substituted, a sulfamoyl group which may be substituted, an acyl group derived from sulfonic acid, a C1-4 alkyl group which may be substituted, a C1-4 alkoxy group which may be substituted, an amino group which may be substituted, a nitro group or a cyano group;
R4 is hydrogen atoms or a hydroxy group;
n is 0 or 1; and
p is 0 or 1 to 4];
or a salt thereof, has potent CCR5 antagonistic activity and can be advantageously used as a medicament for inhibition of HIV infection to human peripheral blood mononuclear cells, especially for the treatment or prevention of AIDS.
Abstract: The invention relates to substituted 1-Phenethylpiperidine compounds, a method for the production thereof, medicaments containing said compounds and the use of said compounds in the production of medicaments.
Type:
Application
Filed:
January 5, 2004
Publication date:
September 2, 2004
Inventors:
Bernd Sundermann, Lambert Hoenen, Helmut Buschmann, Babette-Yvonne Koegel, Elmar Friderichs
Abstract: Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.
Type:
Application
Filed:
December 18, 2003
Publication date:
August 19, 2004
Applicant:
BIOCRYST PHARMACEUTICALS, INC.
Inventors:
Yarlagadda S. Babu, R. Scott Rowland, Pooran Chand, Pravin L. Kotian, Yahya El-Kattan, Shri Niwas
Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
Type:
Application
Filed:
February 6, 2004
Publication date:
August 12, 2004
Inventors:
Macklin Brian Arnold, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
Type:
Application
Filed:
November 24, 2003
Publication date:
August 12, 2004
Applicant:
Pfizer Inc
Inventors:
Scott W. Bagley, Thomas A. Brandt, Robert W. Dugger, William A. Hada, Cheryl M. Hayward, Zhengyu Liu
Abstract: The present invention provides a compound of the formula:
a pharmaceutically acceptable salt or a prodrug thereof, where R1, R2, R3, R4, R5, R6, and n are as defined herein. The present invention also provides compositions comprising, methods for using, and methods for preparing Compound of Formula I.
Abstract: The invention relates to a compound of formula (I), wherein Ar1 represents phenyl, naphthyl or phenyl fused by a C3-8cycloalkyl, where each group is optionally substituted by methylenedioxy or one or two groups independently represented by R1; Ar2 represents phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from halogen, C1-4 alkyl and C1-4 alkoxy; Ar3 represents a phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from hydroxy, alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkenyloxy, C1-4 perfluoroalkoxy, C1-4 acylamino or an electron withdrawing group; A represents —C(H)—; E represents —C1-6 alkylene-; X represents —CON(H or C1-4alkyl)- or —N(H or C1-4alkyl)CO—; Y represents a direct link; R1 represents halogen, —S(C1-4 alkyl)-, —O—(C0-4 alkylene)-R2 or —(C0-4alkylene)-R2, where each alky
Type:
Application
Filed:
December 1, 2003
Publication date:
July 29, 2004
Inventors:
Anne Bouillot, Agnes Bombrun, Bernard Andre Dumaitre, Romain Luc Gosmini, Miles Stuart Congreve, Nigel Grahame Ramsden
Abstract: One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome.
Abstract: Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes.
Type:
Application
Filed:
December 23, 2003
Publication date:
July 22, 2004
Applicant:
The Procter &Gamble Company
Inventors:
Stanislaw Pikul, Norman Eugene Ohler, Kelly Michelle Solinsky, Neil Gregory Almstead, Biswanath De, Michael George Natchus
Abstract: Methods of treating cyclooxygenase-2 mediated disorders comprising administering to a subject a therapeutically effective amount of one or more fluoro-substituted benzenesulfonyl compounds corresponding to Formula I: 1
Type:
Application
Filed:
December 12, 2003
Publication date:
July 15, 2004
Applicant:
Pharmacia Corporation
Inventors:
David L. Brown, Matthew J. Graneto, Cindy L. Ludwig, John M. Molyneaux, John J. Talley
Abstract: This invention relates to the novel use of amide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
Type:
Application
Filed:
July 16, 2003
Publication date:
July 8, 2004
Inventors:
Michael R. Palovich, Katherine L. Widdowson
Abstract: The invention provides a compound of formula (I) wherein: R1 is a group selected from: (a), (b) and (c) or a pharmaceutically acceptable salt thereof or a solvate thereof; compositions containing these compounds, processes for preparing them and their use as modulators of chemokine activity (especially CCR5 activity).
Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
Type:
Application
Filed:
October 6, 2003
Publication date:
June 24, 2004
Inventors:
Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Maria Carmen Valcarce-Lopez, Niels Blume, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M.M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
Abstract: There is provided a compound of formula I,
wherein Het1, R1, R2, R3, X and n have meanings given in the description, which are useful in the prophylaxis and in the treatment of diseases mediated by opiate receptors, such as pruritus.
Type:
Grant
Filed:
March 19, 2002
Date of Patent:
June 15, 2004
Assignee:
Pfizer Inc
Inventors:
Stephen Paul Gibson, Ivan Tommasini, Kimberley Verrier, Christopher James Dutton, David Morris Gethin, Douglas James Critcher, Richard Edward Armer
Abstract: The invention provides a compound of formula (1): wherein R1, R2, R3, R3a, R4, R4a, R5, and R6 are defined; or a pharmaceutically acceptable salt thereof or a solvate thereof; compositions containing these compounds, processes for preparing them and their use as modulators of chemokine activity (especially CCR5 activity).
Type:
Application
Filed:
August 26, 2003
Publication date:
June 10, 2004
Inventors:
Jeremy Burrows, John Cumming, Howard Tucker
Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, R3a, R4, R4a, R5, and R6 are as defined; or a pharmaceutically acceptable salt thereof or a solvate thereof; compositions containing these compounds, processes for preparing them and their use as modulators of chemokine activity (especially CCR5 activity).
Abstract: This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1).
Type:
Application
Filed:
June 11, 2003
Publication date:
June 3, 2004
Applicant:
Millennium Pharmaceuticals, Inc.
Inventors:
Christopher Blackburn, Su-Jen Lai, Jennifer L. Che, Martin P. Maguire, Michael A. Patane, Matthew J. LaMarche, Courtney A. Cullis, James Brown, Anil Vasudevan, Jennifer C. Freeman, Mathew M. Mulhern, John K. Lynch, Ju Gao, Dariusz Wodka, Andrew J. Souers, Rajesh Iyengar, Mary Katherin Verzal, Philip R. Kym
Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..
Type:
Application
Filed:
July 25, 2003
Publication date:
May 27, 2004
Applicant:
AVENTIS PHARMACEUTICALS INC.
Inventors:
William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Aiwen Li, Michael R. Myers, Wan F. Lau, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
Abstract: The present invention discloses compounds which, are novel receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
Type:
Application
Filed:
October 24, 2003
Publication date:
May 27, 2004
Inventors:
Andrew W. Stamford, Ying Huang, Li Guoqing
Abstract: This invention provides compounds of Formula (I), N-oxides and suitable salts thereof, wherein A and B are independently O or S; each J is independently a phenyl ring, a naphthyl ring system, a 5- or 6-membered heteroaromatic ring or an aromatic 8-, 9- or 10-membered fused heterobicyclic ring system wherein each ring or ring system is optionally substituted with 1 to 4 R5; K is, together with the two contiguous linking carbon atoms, a 5- or 6-membered heteroaromatic ring optionally substituted with 1 to 3 R4; and R1, R2, R3, R4, R5 and n are as defined in the disclosure. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula (I), an N-oxide thereof or a suitable salt of the compound (e.g., as a composition described herein).
Type:
Application
Filed:
August 26, 2003
Publication date:
May 27, 2004
Inventors:
Gary David Annis, Bruce Lawrence Finklestein
Abstract: An aromatic sulfonyl alpha-cycloamino hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated aromatic sulfonyl alpha-cycloamino hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
Type:
Application
Filed:
October 27, 2003
Publication date:
May 20, 2004
Applicant:
G.D. Searle & Co.
Inventors:
Hui Li, Daniel P. Becker, Clara I. Villamil, Terri L. Boehm, Daniel P. Getman, Joseph J. McDonald, Gary A. DeCrescenzo